PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, has announced new research published today in Science Translational Medicine, ...
CEO Al Sandrock outlined several 2026 priorities in a discussion focused on the company’s tau-directed pipeline and its newer ...
Speaking at the ELRIG meeting at Hinxton Hall in March, Dr Seng H. Cheng set out how next-generation adeno-associated viral ...
Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of serotypes Kits incorporate Thermo Fisher Scientific’s CaptureSelect affinity reagents for ...
Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Download Brochure Accurate viral vector characterization in ...
The FDA granted priority review, with a decision expected by June 19, 2025. LEN represents a novel class of HIV therapies by targeting the viral capsid, a multifunctional protein essential for HIV ...
The canonical rAAV vector holds ≦ 4.7 kb single-stranded (ss) DNA within a 60-protein icosahedral capsid, and tropism is chosen from 13 known natural and supplementary unique hybrid serotypes enabling ...
Separating full and empty adeno-associated virus (AAV) capsids during the manufacture of single-gene therapies remains a significant challenge. Ultracentrifugation and anion exchange chromatography ...
A significant advancement in molecular engineering has produced a large, hollow spherical shell nanostructure through the self-assembly of peptides and metal ions, report researchers from Japan. This ...
New hollow dodecahedral shell demonstrates remarkable stability and potential for functionalization and encapsulating macromolecules. (Nanowerk News) Controlling the topology and structure of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results